

**RESEARCH TO PREVENT BLINDNESS, INC.
AND
RESEARCH TO PREVENT BLINDNESS
ENDOWMENT FUND, INC.**

**Combined Financial Statements
for year ended
December 31, 2024**

Independent Auditor's Report

To the Board of Trustees
Research to Prevent Blindness, Inc. and
Research to Prevent Blindness Endowment Fund, Inc.

Opinion

We have audited the accompanying combined financial statements of Research to Prevent Blindness, Inc. and Research to Prevent Blindness Endowment Fund, Inc., (collectively, "RPB"), which comprise the combined statement of financial position as of December 31, 2024 and the related combined statements of activities, cash flows and functional expenses for the year then ended and the related notes to the combined financial statements.

In our opinion, the combined financial statements referred to above present fairly, in all material respects, the financial position of RPB as of December 31, 2024 and the results of their net assets and their cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of RPB and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Report on Summarized Comparative Information

We have previously audited RPB's 2023 combined financial statements, and we expressed an unmodified opinion on those audited combined financial statements in our report dated September 5, 2024. In our opinion, the summarized comparative information presented herein as of and for the year ended December 31, 2023, is consistent, in all material respects, with the audited combined financial statements from which it has been derived.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the combined financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of combined financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the combined financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about RPB's ability to continue as a going concern within one year after the date that the combined financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the combined financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the combined financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the combined financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the combined financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of RPB's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the combined financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about RPB's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Condon O'Meara McElroy & Donnelly LLP

August 12, 2025

RESEARCH TO PREVENT BLINDNESS

Combined Statement of Financial Position

Assets

	December 31	
	2024	2023
Cash and cash equivalents	\$ 9,744,059	\$ 8,951,148
Investments, at fair value	295,041,713	281,508,184
Due from investment managers	-	1,092,397
Interest and other receivables	53,747	146,343
Contributions receivable, net	649,634	1,055,087
Prepaid expenses	203,622	175,757
Assets designated for deferred compensation plan	121,130	87,176
Equipment, website and leasehold improvements, at cost, net		
Equipment (less accumulated depreciation of \$347,969 in 2024 and \$334,867 and 2023)	34,289	45,031
Website (work-in-progress)	104,583	78,750
Leasehold improvements, (less accumulated amortization of \$69,264 in 2024 and \$61,003 in 2023)	53,854	62,115
Right-of-use asset, net – operating lease	1,865,518	2,171,102
Total assets	<u>\$307,872,149</u>	<u>\$295,373,090</u>

Liabilities and Net Assets

Liabilities

Accounts payable and accrued expenses	\$ 201,748	\$ 336,861
Grants payable, net	11,251,331	11,228,870
Deferred compensation plan	121,130	87,176
Unearned revenue	32,500	7,500
Operating lease liability, net	2,096,571	2,416,991
Total liabilities	<u>13,703,280</u>	<u>14,077,398</u>

Net assets

Without donor restrictions		
General operating	214,469,679	199,048,119
Designated	16,462,496	18,242,895
Total without donor restrictions	230,932,175	217,291,014
With donor restrictions	63,236,694	64,004,678
Total net assets	<u>294,168,869</u>	<u>281,295,692</u>
Total liabilities and net assets	<u>\$307,872,149</u>	<u>\$295,373,090</u>

See notes to combined financial statements.

RESEARCH TO PREVENT BLINDNESS

Combined Statement of Activities
Year Ended December 31, 2024
(With Summarized Comparative Information for the Year Ended December 31, 2023)

	2024					2023
	Without Donor Restrictions			With Donor Restrictions		
	General Operating	Designated	Total		Total	Total
Public support and revenue						
Public support						
Contributions	\$ 2,945,399	\$ -	\$ 2,945,399	\$ 2,006,654	\$ 4,952,053	\$ 3,119,870
Combined Federal Campaign	820	-	820	-	820	1,058
Ophthalmological associate memberships	19,250	-	19,250	-	19,250	24,700
Donated investments	53,082	-	53,082	-	53,082	2,035
Total public support	3,018,551	-	3,018,551	2,006,654	5,025,205	3,147,663
Revenue						
Interest and dividends, net	6,431,563	19,939	6,451,502	447,802	6,899,304	4,382,560
Net limited partnership income	3,988,963	-	3,988,963	51,100	4,040,063	10,705,713
Other	2,227	-	2,227	-	2,227	97,551
Total revenue	10,422,753	19,939	10,442,692	498,902	10,941,594	15,185,824
Net assets released from restrictions or designations						
Satisfaction of program restrictions or designations	4,110,241	(1,803,571)	2,306,670	(2,306,670)	-	-
Satisfaction of Matching Fund restrictions	1,000,000	-	1,000,000	(1,000,000)	-	-
Total net assets released from restrictions or designations	5,110,241	(1,803,571)	3,306,670	(3,306,670)	-	-
Total public support and revenue	18,551,545	(1,783,632)	16,767,913	(801,114)	15,966,799	18,333,487
Expenses						
Program services						
Research grants, net of refunded and canceled grants of \$17,102 in 2024 and \$148,020 in 2023	12,000,360	-	12,000,360	-	12,000,360	10,942,523
Direct research support	680,106	-	680,106	-	680,106	616,441
Program development to stimulate laboratory expansion and eye research activities	464,547	-	464,547	-	464,547	427,711
Scientific symposia, seminars and surveys	374,857	-	374,857	-	374,857	358,456
Public and professional information	939,607	-	939,607	-	939,607	904,888
Total program services	14,459,477	-	14,459,477	-	14,459,477	13,250,019
Supporting activities						
Management and general	778,036	-	778,036	-	778,036	678,774
Fund raising	97,056	-	97,056	-	97,056	96,034
Total supporting activities	875,092	-	875,092	-	875,092	774,808
Total expenses	15,334,569	-	15,334,569	-	15,334,569	14,024,827
Excess (deficiency) of revenue over expenses before net realized gains and change in unrealized gains on investments	3,216,976	(1,783,632)	1,433,344	(801,114)	632,230	4,308,660
Net realized gains and change in unrealized gains on investments	12,204,584	3,233	12,207,817	33,130	12,240,947	8,296,823
Increase (decrease) in net assets	15,421,560	(1,780,399)	13,641,161	(767,984)	12,873,177	12,605,483
Net assets, beginning of year	199,048,119	18,242,895	217,291,014	64,004,678	281,295,692	268,690,209
Net assets, end of year	\$ 214,469,679	\$ 16,462,496	\$ 230,932,175	\$ 63,236,694	\$ 294,168,869	\$ 281,295,692

See notes to combined financial statements.

RESEARCH TO PREVENT BLINDNESS

Combined Statement of Cash Flows

	Year Ended December 31	
	2024	2023
Cash flows from operating activities		
Cash received from contributions	\$ 5,402,576	\$ 3,616,256
Interest and dividends received	7,437,771	4,834,056
Miscellaneous receipts	2,227	97,551
Cash paid to employees and suppliers	(3,936,532)	(3,508,161)
Grants paid	(11,977,898)	(10,561,948)
Net cash (used in) operating activities	(3,071,856)	(5,522,246)
Cash flows from investing activities		
Purchase of equipment, website and leasehold improvements	(28,193)	(115,517)
Sales and maturities of investments	64,348,532	158,500,347
Purchase of investments	(60,455,572)	(153,973,328)
Net cash provided by investing activities	3,864,767	4,411,502
Net increase (decrease) in cash and cash equivalents	792,911	(1,110,744)
Cash and cash equivalents, beginning of year	8,951,148	10,061,892
Cash and cash equivalents, end of year	\$ 9,744,059	\$ 8,951,148

See notes to combined financial statements.

RESEARCH TO PREVENT BLINDNESS

Combined Statement of Functional Expenses

Year Ended December 31, 2024

(With Summarized Comparative Information for the Year Ended December 31, 2023)

	2024								2023
	Program Services					Supporting Activities			
	Research Grants, net and Direct Research Support	Program Development	Scientific Symposia, Seminars and Surveys	Public and Professional Information	Total	Management and General	Fund Raising	Total	Total
Grants, net	\$12,000,360	\$ -	\$ -	\$ -	\$12,000,360	\$ -	\$ -	\$ 12,000,360	\$ 10,942,523
Salaries, pension and benefits	312,739	274,115	234,955	704,867	1,526,676	372,013	58,739	1,957,428	1,867,627
Professional fees and services	53,049	34,987	20,074	48,559	156,669	252,129	5,396	414,194	315,376
Conferences, seminars, meetings and travel	162,500	48,549	48,013	4,877	263,939	3,771	-	267,710	213,972
Telecommunications	2,230	3,065	5,573	15,325	26,193	1,393	279	27,865	25,070
Printing, stationery, postage and shipping	4,411	7,138	4,145	26,092	41,786	2,390	15,710	59,886	69,934
Office supplies, maintenance and occupancy	129,241	84,442	52,679	114,941	381,303	48,488	13,311	443,102	417,905
Dues, subscriptions, insurance and miscellaneous	9,099	7,979	7,282	19,605	43,965	95,716	2,980	142,661	151,487
Depreciation and amortization	6,837	4,272	2,136	5,341	18,586	2,136	641	21,363	20,933
Total expenses – 2024	\$12,680,466	\$ 464,547	\$ 374,857	\$ 939,607	\$14,459,477	\$ 778,036	\$ 97,056	\$ 15,334,569	
Total expenses – 2023	\$11,558,964	\$ 427,711	\$ 358,456	\$ 904,888	\$13,250,019	\$ 678,774	\$ 96,034		\$14,024,827

See notes to combined financial statements.

RESEARCH TO PREVENT BLINDNESS

Notes to Combined Financial Statements December 31, 2024

Note 1 – Nature of organization

Research to Prevent Blindness, Inc. (“RPB”) is a publicly supported charity formed in 1960 for the purpose of providing the organizational and financial resources necessary to support a comprehensive program of eye research.

In May 1988, Research to Prevent Blindness Endowment Fund, Inc. (“RPBEF”) was incorporated with its purpose being to support and benefit RPB and efficiently manage the assets of certain endowment funds. The officers of RPBEF are also officers of RPB. Both organizations are collectively referred to as Research to Prevent Blindness or RPB.

RPBEF makes financial grants to institutions engaged in eye research.

Research to Prevent Blindness, Inc. is exempt from Federal income taxes under Section 501(c)(3) of the Internal Revenue Code and is classified as a publicly supported charity described in Section 509(a)(1) of the Internal Revenue Code. Research to Prevent Blindness Endowment Fund, Inc. operates as a support organization exempt from Federal income taxes under Section 501(c)(3) of the Internal Revenue Code and is classified as a publicly supported charity described in Section 509(a)(3) of the Internal Revenue Code.

Note 2 – Summary of significant accounting policies

Basis of presentation

The accompanying combined financial statements include the accounts of RPB and its support organization, RPBEF. The effects of all transactions between RPB and RPBEF have been eliminated upon combination.

Net assets

Net assets consist of revenue, expenses, investment return and other support that are classified based on the existence or absence of donor-imposed restrictions. The net assets of RPB and changes therein are classified and reported as follows:

- Net assets without donor restrictions represent resources over which the Board of Trustees has full discretion with respect to use.
- Net assets with donor restrictions consist of net assets that are temporarily and perpetually donor restricted.

Net assets with temporary donor restrictions represent expendable resources, which have been time or purpose restricted by the donor (see note 12). When a donor restriction expires, that is, when a stipulated time restriction ends or a purpose restriction is accomplished, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the combined statement of activities as net assets released from restrictions.

Net assets with perpetual donor restrictions represent contributions and other gifts, which require that the corpus be maintained intact and that only the income be used as designated by the donor (see note 12).

RESEARCH TO PREVENT BLINDNESS**Notes to Combined Financial Statements (continued)
December 31, 2024****Note 2 – Summary of significant accounting policies (continued)****Contributions**

Bequests are recorded as revenue when a legally binding obligation is received and when a fair value can reasonably be determined.

Cash equivalents

RPB considers short-term investments with original maturities of 90 days or less to be cash equivalents. Included in cash equivalents are money market funds.

Fair values of financial instruments

RPB's financial instruments consist of cash, cash equivalents, investments and interest receivable. RPB estimates that the fair value of all financial instruments as of December 31, 2024 does not differ materially from the aggregate carrying values of its financial instruments recorded in the accompanying combined statement of financial position. The carrying amounts of cash, cash equivalents and interest receivable reported in the combined statement of financial position approximate fair value because of the short maturities of those instruments. The fair value of investment securities is based on quoted market prices for those investments. The value of the alternative investments, which is adjusted for unrealized appreciation (depreciation), is based upon the most recent available information provided by management of the funds and may differ from the value that would have been used had a ready market for the alternative investments existed.

Equipment, website and leasehold improvements

RBP's policy is to capitalize equipment, website and leasehold improvements over \$1,000 with an estimated useful life of more than one year. Depreciation of equipment is calculated on a straight-line basis over the estimated useful lives of between three and five years. The website will be amortized over an estimated useful life of ten years once the project is completed. Leasehold improvements are amortized over the term of the lease or the estimated useful life, whichever is shorter. During 2023, RPB wrote-off fully depreciated assets with an original cost basis of \$61,986.

Grants payable

RPB records grants when the Board of Trustees approves them. Long-term grants are discounted to their present value using a rate of 5% to reflect the time value of money. Amortization of the discount to par value is reported as grant expense.

Operating lease liability

RPB has elected to use a risk-free rate to discount its office lease liability to its net present value. RPB has also elected to not record leases with an initial term of 12 months or less on the combined statement of financial position.

RESEARCH TO PREVENT BLINDNESS

Notes to Combined Financial Statements (continued) December 31, 2024

Note 2 – Summary of significant accounting policies (continued)

Functional allocation of expenses

Salaries are generally allocated to the various program services and supporting activities based on the amount of time spent by specific individuals on each service and activity. Fringe benefits and other employee costs are allocated on an overall basis, corresponding generally to the allocation of salary expenses. All other expenses can generally be identified with the program service or supporting activity to which they relate.

Use of estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the combined financial statements. Actual results could differ from these estimates.

Concentrations of credit risk

RPB's financial instruments that are potentially exposed to concentrations of credit risk consist primarily of cash, cash equivalents, investments and receivables. RPB places its cash and cash equivalents with what it believes to be quality financial institutions. At times during the year, RPB's balances in its bank accounts were in excess of the FDIC insurance limit. RPB has not experienced any losses in such accounts to date. RPB's investments are exposed to various risks such as interest rate, market volatility, liquidity and credit risks. Due to the level of uncertainty related to these risks, it is reasonably possible that changes in these risks could affect the fair value of the investments reported in the combined statement of financial position at December 31, 2024. RPB routinely assesses the financial strength of its cash, cash equivalents and investment portfolio and monitors the collectability of its receivables. As a consequence, concentrations of credit risk are believed to be limited.

Comparative financial information

The combined financial statements include certain prior year summarized comparative information in total, but not by net asset class or functional expense classification. Such information does not include sufficient detail to constitute a presentation in conformity with accounting principles generally accepted in the United States of America. Accordingly, such information should be read in conjunction with RPB's combined financial statements for the year ended December 31, 2023, from which the summarized information was derived.

Subsequent events

RPB has evaluated events and transactions for potential recognition or disclosure through August 12, 2025, which is the date the combined financial statements were available to be issued.

RESEARCH TO PREVENT BLINDNESS

Notes to Combined Financial Statements (continued) December 31, 2024

Note 3 – Liquidity and availability of financial assets

RPB regularly monitors the availability of resources required to meet its operating needs and other commitments while also striving to maximize the investment of its available funds. For purposes of analyzing resources available to meet general expenditures over a 12-month period, RPB considers all expenditures related to its ongoing grant-making activities to be general expenditures.

The following reflects RPB's financial assets as of December 31, 2024 and December 31, 2023, reduced by amounts not available for general use within one year of the combined statement of financial position date because of contractual or donor-imposed restrictions:

	<u>2024</u>	<u>2023</u>
Financial assets		
Cash and cash equivalents	\$ 9,744,059	\$ 8,951,148
Investments, at fair value	295,041,713	281,508,184
Due from investment managers	-	1,092,397
Interest and other receivables	53,747	146,343
Contributions receivable, current	<u>430,000</u>	<u>680,000</u>
Sub-total	305,269,519	292,378,072
Less: Designated net assets	(16,462,496)	(18,242,895)
Net assets with donor restrictions not expected to be met within one year	<u>(60,123,306)</u>	<u>(61,026,242)</u>
Total	<u>\$ 228,683,717</u>	<u>\$ 213,108,935</u>

Note 4 – Investments, at fair value

Due from investment managers

The amount due from investment managers as of December 31, 2023 was \$1,092,397 which consists of a 5% holdback from the liquidation of a hedge fund. It was subsequently received in April 2024.

Fair value measurements

Fair value refers to the price that would be received to sell an asset in an orderly transaction between market participants at the measurement date. The fair value hierarchy gives the highest priority to quoted market prices in active markets and the lowest priority to unobservable data. Fair value measurements are required to be separately disclosed by level within the fair value hierarchy. The three levels of inputs used to measure fair value are as follows:

Level 1 – Quoted prices in active markets for identical assets.

Level 2 – Observable inputs other than level 1 prices such as quoted prices of similar assets; quoted prices in markets with insufficient volume or infrequent transactions (less than active markets).

Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets.

RESEARCH TO PREVENT BLINDNESS

Notes to Combined Financial Statements (continued) December 31, 2024

Note 4 – Investments, at fair value (continued)

Fair value measurements

The fair value of the RPB's investments in hedge, emerging markets, global, commodity and discretionary macro funds are determined using the net asset value ("NAV") per share and are not included in the fair value hierarchy.

Accounting standards require the presentation of the carrying amount of investments measured using the NAV practical expedient as a reconciling item between the total amount of investments categorized within the fair value hierarchy and the total investments measured at fair value on the face of the combined financial statements.

The following is a summary of investments measured at fair value at December 31, 2024 and December 31, 2023:

	2024			
	Total	Quoted Prices in Active Markets For Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Mutual funds				
Equity				
Emerging markets	\$ 9,071,359	\$ 9,071,359	\$ -	\$ -
Small cap	3,495,710	3,495,710	-	-
Mid cap	744,860	744,860	-	-
International index	14,200,037	14,200,037	-	-
S&P 500	24,875,522	24,875,522	-	-
Bond				
Corporate bond funds	68,933,493	68,933,493	-	-
Commodity				
Strategy fund	24,168,374	24,168,374	-	-
Total mutual funds	<u>145,489,355</u>	<u>145,489,355</u>	<u>-</u>	<u>-</u>
Exchange-traded funds				
Global equity	30,468,656	30,468,656	-	-
S&P 500	3,120,788	3,120,788	-	-
Total exchange-traded funds	<u>33,589,444</u>	<u>33,589,444</u>	<u>-</u>	<u>-</u>
U.S. Treasury Bills	<u>21,597,554</u>	<u>21,597,554</u>	<u>-</u>	<u>-</u>
Alternative investments				
Master limited partnership	10,481,530	-	-	10,481,530
Private credit fund	1,926,103	-	-	1,926,103
Private equity fund	2,798,642	-	-	2,798,642
Total alternative investments	<u>15,206,275</u>	<u>-</u>	<u>-</u>	<u>15,206,275</u>
Total investments measured in the fair value hierarchy	215,882,628	<u>\$ 200,676,353</u>	<u>\$ -</u>	<u>\$ 15,206,275</u>
Investments measured at NAV				
Hedge funds	18,901,351			
Limited partnership				
Emerging markets	7,403,651			
Limited liability company				
Global fund	15,842,226			
Commodity fund	10,012,229			
Discretionary macro fund	26,999,628			
Total investments at fair value	<u>\$ 295,041,713</u>			

RESEARCH TO PREVENT BLINDNESS

Notes to Combined Financial Statements (continued) December 31, 2024

Note 4 – Investments, at fair value (continued)

	2023			
	Total	Quoted Prices in Active Markets For Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Mutual funds				
Equity				
Emerging markets	\$ 9,565,816	\$ 9,565,816	\$ -	\$ -
Small cap	3,550,011	3,550,011	-	-
International index	12,314,375	12,314,375	-	-
S&P 500	23,191,370	23,191,370	-	-
Bond				
Corporate bond funds	55,963,203	55,963,203	-	-
Inflation-protected	6,154,579	6,154,579	-	-
Commodity				
Real return	13,541,366	13,541,366	-	-
Total mutual funds	<u>124,280,720</u>	<u>124,280,720</u>	<u>-</u>	<u>-</u>
Exchange-traded funds				
Global equity	28,700,401	28,700,401	-	-
S&P 500	2,539,118	2,539,118	-	-
Large cap	3,232,974	3,232,974	-	-
International index	2,243,873	2,243,873	-	-
Gold	3,681,661	3,681,661	-	-
Total exchange-traded funds	<u>40,398,027</u>	<u>40,398,027</u>	<u>-</u>	<u>-</u>
U.S. Treasury Bills	<u>27,986,671</u>	<u>27,986,671</u>	<u>-</u>	<u>-</u>
Alternative investments				
Master limited partnership	8,453,156	-	-	8,453,156
Private credit fund	1,582,945	-	-	1,582,945
Private equity fund	1,781,721	-	-	1,781,721
Total alternative investments	<u>11,817,822</u>	<u>-</u>	<u>-</u>	<u>11,817,822</u>
Total investments measured in the fair value hierarchy	204,483,240	<u>\$ 192,665,418</u>	<u>\$ -</u>	<u>\$ 11,817,822</u>
Investments measured at NAV				
Hedge funds	19,379,312			
Limited partnership				
Emerging markets	7,576,088			
Limited liability company				
Global fund	15,553,609			
Commodity fund	9,707,002			
Discretionary macro fund	<u>24,808,933</u>			
Total investments at fair value	<u>\$ 281,508,184</u>			

RPB uses the net asset value (NAV), or its equivalent, to determine the fair value of all the underlying investments which: (a) do not have a readily determinable fair value and (b) prepare their financial statements consistent with the measurement principles of an investment company or have the attributes of an investment company.

RESEARCH TO PREVENT BLINDNESS

Notes to Combined Financial Statements (continued) December 31, 2024

Note 4 – Investments, at fair value (continued)

The table below lists the restrictions on withdrawals and the redemption terms of RPB's investments:

<u>Type/Fund</u>	<u>Investment Strategy</u>	<u>Redemption Terms</u>
Hedge Funds – 1	Multi-strategy invested in equities	Last business day of each calendar month
Master Limited Partnership – 1	Securities and other tangible investment instruments	Within 30 business days from the redemption date
Limited Partnership – 3	To maximize long-term capital appreciation by investing in equity securities or equity-linked instruments of companies worldwide	Weekly
	Private investment fund that invests in specialized direct lending, opportunistic credit, distressed debt and special situations strategies across global credit markets	Redemptions will be made at the discretion of the fund.
	Private investment fund that will invest in buyout, venture capital, growth equity and special situations strategies across global private equity markets	Redemptions will be made at the discretion of the fund.
Limited Liability Company – 1	Borrowing and lending securities	1 day
Commodity Fund – 1	Global macro strategy that invests in both long and short positions across global interest rates, currencies, equity markets and commodities	Monthly liquidity – 1 st of each month with 5 days notice
Discretionary Macro Fund – 1	Global macro strategy that invests in both long and short positions across global interest rates, currencies, equity markets and commodities	Monthly liquidity – 1 st of each month with 5 days notice

The table below outlines RPB's capital commitments related to its private equity and private credit investments as of December 31, 2024:

<u>Commitment Date</u>	<u>Total Commitment</u>	<u>Net Capital Contributions</u>	<u>Remaining Commitment</u>
September 2022	\$ 3,000,000	\$ 1,681,049	\$ 1,318,951
September 2022	<u>6,000,000</u>	<u>2,842,964</u>	<u>3,157,036</u>
Total	<u>\$ 9,000,000</u>	<u>\$ 4,524,013</u>	<u>\$ 4,475,987</u>

RESEARCH TO PREVENT BLINDNESS

Notes to Combined Financial Statements (continued) December 31, 2024

Note 5 – Contributions receivable, net

As of December 31, 2024 and December 31, 2023, contributions receivable are due as follows:

<u>Year</u>	<u>2024</u>	<u>2023</u>
2024	\$ -	\$ 680,000
2025	430,000	480,000
2026	305,000	30,000
Sub-total	735,000	1,190,000
Less: discount to present value	(85,366)	(134,913)
Net contributions receivable	<u>\$ 649,634</u>	<u>\$ 1,055,087</u>

Note 6 – Grants payable, net

As of December 31, 2024 and December 31, 2023, grants payable are due as follows:

<u>Year</u>	<u>2024</u>	<u>2023</u>
2024	\$ -	\$ 6,608,000
2025	7,372,000	3,775,000
2026	3,150,000	1,275,000
2027	1,175,000	400,000
2028	400,000	-
Sub-total	12,097,000	12,058,000
Less: discount to present value	(845,669)	(829,130)
Net grants payable	<u>\$ 11,251,331</u>	<u>\$ 11,228,870</u>

Note 7 – Lease commitment

In August 2015, RPB signed a lease for new office space at 360 Lexington Avenue, New York, New York which expires on August 31, 2031. In connection with the lease agreement, RPB provided the landlord an irrevocable letter of credit of \$102,069 as security for the lease agreement.

In connection with the lease agreement, RPB received eight months of free rent. Total rent expense amounted to \$343,860 and \$329,158 in 2024 and 2023, respectively, and is included in office supplies, maintenance and occupancy on the combined statement of functional expenses.

Future obligations under the lease, excluding escalation charges, are as follows at December 31, 2024:

<u>Year</u>	<u>Amount</u>
2025	\$ 336,548
2026	343,383
2027	363,888
2028	363,888
2029	363,888
2030 and thereafter	606,480
Total	2,378,075
Less: present value discount	(281,504)
Operating lease liability	<u>\$ 2,096,571</u>

RESEARCH TO PREVENT BLINDNESS**Notes to Combined Financial Statements (continued)
December 31, 2024****Note 8 – Retirement plans****Defined contribution plan**

RPB has a defined contribution retirement plan covering all of its employees. Employees are vested on an incremental scale during their first six years of employment; thereafter, they are 100% vested. The plan expense for the years ended December 31, 2024 and December 31, 2023 totaled \$277,174 and \$278,810, respectively.

Deferred compensation plan

In 2020, RPB established a 457(b) deferred compensation plan for a key management employee. The plan assets remain assets of RPB until paid to the employee. Accordingly, the amount deferred is reflected as an asset and liability on the accompanying combined statement of financial position. For the years ended December 31, 2024 and December 31, 2023, contributions charged to operations for this plan were \$23,000 and \$22,500, respectively.

The 457(b) plan, which is represented by investments in a fixed income fund and an equity mutual fund, amounted to \$121,130 and \$87,176 at December 31, 2024 and December 31, 2023, respectively. For assets measured at fair value on a recurring basis, accounting standards require quantitative disclosures about the fair value measurement separately for each major class of assets. The 457(b) plan's assets, consisting of publicly traded mutual funds, have been classified in the highest level of hierarchy (Level 1). Their quoted prices are in active markets for identical assets.

Note 9 – Designated funds – Stein Innovation Awards and the David F. Weeks Awards

The Board of Trustees of RPB designated funds from net assets without donor restrictions to assure adequate financial support for the Stein Innovation Awards (formerly Jules and Doris Stein RPB Professorship Grants) and the David F. Weeks Awards. The grants awarded below include the change in the discount during 2024 and 2023.

Stein Innovation Awards

During 1986, the Board of Trustees of RPB designated funds from net assets without donor restrictions of \$11,500,000 to assure adequate financial support for the Jules and Doris Stein RPB Professorship Grants (which is now the Stein Innovation Awards). During 1995, the Board designated an additional \$30,000,000 for this purpose. In addition, during 2005, the Board designated an additional \$4,971,303 for this purpose. The Stein Innovation Awards provide grants of \$300,000 over 2 years for senior scientists to start a new and innovative line of vision research. Payments are not subject to annual renewal by the Board. Stein Innovation Awards totaling approximately \$1,800,000 and \$1,200,000 were awarded in 2024 and 2023, respectively. The balance of such designated funds amounted to \$15,861,619 and \$17,640,190 at December 31, 2024 and December 31, 2023, respectively.

RESEARCH TO PREVENT BLINDNESS

Notes to Combined Financial Statements (continued) December 31, 2024

Note 9 – Designated funds – Stein Innovation Awards and the David F. Weeks Awards (continued)

David F. Weeks Awards

In 2016, an anonymous donor contributed \$500,000 to RPB as a restricted gift in partial support of an award honoring RPB Chair Emeritus David F. Weeks. During 2017, an additional \$125,655 was contributed to this fund which was also matched by RPB. The following conditions were applied to the Award:

- The \$500,000 gift was matched by \$500,000 from RPB with the total \$1,000,000 held in restriction and invested in a Vanguard S&P 500 ETF. RPB's contribution is held as a Board designated fund.
- From this account an annual award of \$40,000 would be granted from RPB to the Association of University Programs in Ophthalmology (AUPO) to be given as an unrestricted prize to a researcher chosen by a special AUPO committee. In 2020, the award was increased to \$50,000 annually. The award will be given annually for at least 20 years and only U.S. researchers are eligible.

Designated fund activity for the years ended December 31, 2024 and December 31, 2023 is as follows:

	<u>2024</u>	<u>2023</u>
Stein Innovation Awards		
Balance, beginning of year	\$ 17,640,190	\$ 18,847,333
Grants awarded	<u>(1,778,571)</u>	<u>(1,207,143)</u>
Balance, end of year	<u>15,861,619</u>	<u>17,640,190</u>
David F. Weeks Awards		
Balance, beginning of year	602,705	594,958
Investment return	23,172	32,747
Grants awarded	<u>(25,000)</u>	<u>(25,000)</u>
Balance, end of year	<u>600,877</u>	<u>602,705</u>
Total designated funds, at year-end	<u>\$ 16,462,496</u>	<u>\$ 18,242,895</u>

Note 10 – Jules and Doris Stein Matching Fund

During 1984, the Jules and Doris Stein Foundation contributed \$10,756,710 to RPB to establish the Jules and Doris Stein Matching Fund (the "Fund"). This Fund, which commenced in the beginning of 1985, enables RPB to continue Dr. and Mrs. Stein's traditional year-end offers to match up to \$1,000,000 in contributions from others. The principal from the Fund may be used for matching only to the extent that there is insufficient investment return. Investment return earned in excess of the matching requirements is added to the Fund balance.

RESEARCH TO PREVENT BLINDNESS

Notes to Combined Financial Statements (continued) December 31, 2024

Note 10 – Jules and Doris Stein Matching Fund (continued)

The Fund had contributions totaling \$2,075 and net investment return of \$155,979 (interest, dividends, net limited partnership income and realized/capital gains and losses) for the year ended December 31, 2024, and contributions totaling \$39,837 and net investment return of \$230,525 for the year ended December 31, 2023. In accordance with the terms of the Fund, \$1,000,000 was released in both 2024 and 2023 for the general programs and activities of RPB to match contributions received during these years.

As a result, the principal of the Fund was decreased by \$(841,946) and \$(729,638) during the years ended December 31, 2024 and December 31, 2023, respectively.

Note 11 – David F. Weeks Awards

The following is a summary of the David F. Weeks Awards fund balances as of December 31, 2024 and December 31, 2023:

	<u>2024</u>	<u>2023</u>
Without donor restrictions – designated	\$ 600,877	\$ 602,705
With temporary donor restrictions	<u>600,879</u>	<u>602,707</u>
Total	<u>\$ 1,201,756</u>	<u>\$ 1,205,412</u>

Note 12 – Net assets with donor restrictions

Endowments

RPB classifies as net assets with perpetual donor restrictions the original value of gifts donated to the permanent endowment. The portion of the donor-restricted endowment fund that is not classified as net assets with perpetual donor restrictions is classified as being without donor restrictions and with temporary donor restrictions based on donor stipulations.

RPB's long-term assets shall be invested in accordance with sound investment practices that emphasize long-term investment fundamentals. In establishing the investment objectives of RPB, the Board of Trustees takes into account a number of factors including the financial needs and circumstances of RPB, the time horizon available for investment, the nature of RPB's cash flows and liabilities, and other factors that affect their risk tolerance.

RPB has a policy of spending the investment return generated from its perpetually donor restricted funds, which is allowable under the donor guidelines. At December 31st, any unspent donor-restricted investment return is added to the balance with temporary donor restrictions of the appropriate fund. This is consistent with RPB's objective to maintain the purchasing power of the endowment assets held in perpetuity as well as to provide additional growth through investment return and new gifts.

RESEARCH TO PREVENT BLINDNESS

Notes to Combined Financial Statements (continued) December 31, 2024

Note 12 – Net assets with donor restrictions (continued)

Net assets with perpetual donor restrictions

These net assets represent contributions and bequests made into the following funds and are restricted to investment in perpetuity. Investment return from these funds is available for unrestricted use except with respect to the William & Mary Greve Memorial Fund, the Dolly Green Fund, the two Sybil B. Harrington Funds and the John D. and Patricia Sakona Endowment Fund, and The Ernest E. and Elizabeth P. Althouse Memorial Fund where investment return is classified as being with temporary donor restrictions. Investment return from the David B. Sykes Endowment Fund is classified as being with perpetual donor restrictions for annual earnings up to 4%. Annual earnings in excess of 4% are classified as being with temporary donor restrictions.

Activity of the net assets with perpetual donor restrictions for the year ended December 31, 2024 is as follows:

	Balance at December 31, 2023	Investment Return	Balance at December 31, 2024
Jules & Doris Stein Endowment Fund	\$ 45,087,782	\$ -	\$ 45,087,782
Lew R. & Edie Wasserman Fund	1,407,412	-	1,407,412
Sybil B. Harrington Macular Degeneration Fund	1,500,000	-	1,500,000
Sybil B. Harrington Eye Disease Fund	1,500,000	-	1,500,000
William & Mary Greve Memorial Fund	519,943	-	519,943
Dolly Green Fund	500,000	-	500,000
Desiree L. Franklin Endowment Fund	138,700	-	138,700
Eugene G. Blackford Memorial Fund	28,000	-	28,000
John D. and Patricia Sakona Endowment Fund	75,453	-	75,453
David B. Sykes Endowment Fund	321,708	12,369	334,077
The Ernest E. and Elizabeth P. Althouse Memorial Fund	2,193,667	-	2,193,667
Edwin Malloy Jr. Memorial Fund	219,656	-	219,656
Total net assets with perpetual donor restrictions	<u>\$ 53,492,321</u>	<u>\$ 12,369</u>	<u>\$ 53,504,690</u>

RESEARCH TO PREVENT BLINDNESS

Notes to Combined Financial Statements (continued) December 31, 2024

Note 12 – Net assets with donor restrictions (continued)

Net assets with temporary donor restrictions

Activity of the net assets with temporary donor restrictions for the year ended December 31, 2024 is as follows:

	Balance at December 31, 2023	Contributions	Net Assets Released from Restrictions	Investment Return (includes realized gains/losses and net limited partnership income/loss)	Balance at December 31, 2024
Jules & Doris Stein Matching Fund	\$ 3,094,829	\$ 2,075	\$ (1,000,000)	\$ 155,979	\$ 2,252,883
Income available from the Sybil B. Harrington Macular Degeneration Fund	238,453	-	(132,500)	67,432	173,385
Income available from the Sybil B. Harrington Eye Disease Fund	224,839	-	(125,000)	66,238	166,077
Income available from the David B. Sykes Endowment Fund	-	-	-	834	834
Income available from the William & Mary Greve Memorial Fund	487,851	-	(60,000)	43,023	470,874
Income available from the Dolly Green Fund	38,429	-	(25,000)	23,281	36,710
Walt & Lilly Disney Foundation	150,000	150,000	(150,000)	-	150,000
John D. & Patricia Sakona Fund	2,529	-	-	3,126	5,655
The Ernest E. and Elizabeth P. Althouse Memorial Fund	420,347	-	(75,000)	104,423	449,770
Lion's Club International	273,289	-	(75,000)	-	198,289
David F. Weeks Awards	602,707	-	(25,000)	23,172	600,879
Free Family Foundation	808,621	338,489	(400,000)	-	747,110
Income available from the Edwin Malloy Jr. Memorial Fund	-	-	(9,015)	9,015	-
International Retinal Research Foundation	75,000	143,027	(75,000)	-	143,027
Ann Savina Baur Revocable Trust	703,055	-	(150,000)	23,140	576,195
American Macular Degeneration Foundation	256,735	150,000	(150,000)	-	256,735
Thomas Wertheimer	766,373	-	(303,873)	-	462,500
CDA Appeal	500	-	(500)	-	-
Glaucoma Foundation	75,000	-	(75,000)	-	-
Aerie Pharmaceuticals	75,000	-	-	-	75,000
Arthur T. Cantwell Charitable Foundation	20,000	22,500	(20,000)	-	22,500
Vernon F. & Mae E. Thompson Charitable Foundation	15,000	15,000	(15,000)	-	15,000
The American Osteopathic Colleges of Ophthalmology & Otolaryngology	104,101	4,085	(90,000)	-	18,186
Estate of Ana O. Le Roy	718,162	-	(17,200)	-	700,962
Janssen Scientific Affairs, LLC	-	30,000	(15,000)	-	15,000
Mary Tyler Moore & S. Robert Levine, MD Charitable Foundation	415,630	13,945	(75,000)	-	354,575
David Brenner	500,000	-	(37,500)	-	462,500

RESEARCH TO PREVENT BLINDNESS

Notes to Combined Financial Statements (continued) December 31, 2024

Note 12 – Net assets with donor restrictions (continued)

Net assets with temporary donor restrictions (continued)

	Balance at December 31, 2023	Contributions	Net Assets Released from Restrictions	Investment Return (includes realized gains/losses and net limited partnership income/loss)	Balance at December 31, 2024
Albert G. and Olive H. Schlink Foundation	\$ -	\$ 15,000	\$ -	\$ -	\$ 15,000
Leona Budke Memorial	-	300	(300)	-	-
Richard Baker	25,000	-	(25,000)	-	-
Founders Pledge	300,000	300,000	(75,000)	-	525,000
Alice J. Workman Trust	57,800	-	(57,800)	-	-
Nancy Smith	2,500	3,000	(2,500)	-	3,000
William G. and Helen C. Hoffman Foundation	-	15,000	(15,000)	-	-
Diann Messuri	200	-	-	-	200
Daniel and Rebecca Love Charitable Gift Fund	400	-	(400)	-	-
Adrienne Wankiewicz	7	-	(7)	-	-
Josephine and Herbert Gleis Foundation	60,000	-	-	-	60,000
Geraldine Valicenti	-	75	(75)	-	-
Abbvie	-	30,000	(30,000)	-	-
Ivan Ekhaus	-	1,000	-	-	1,000
Patricia Eichman	-	100	-	-	100
Dottie Tarvestad	-	1,250	-	-	1,250
Helen Wood	-	1,000	-	-	1,000
Eugenia Chang	-	250	-	-	250
Eve Doyle	-	3,760	-	-	3,760
Sandra Bauer Lay	-	1,000	-	-	1,000
Manowitz and Drillings Family Foundation	-	5,000	-	-	5,000
Onienell H. Olmsted Trust	-	685,298	-	-	685,298
Walter Renfflen	-	75,000	-	-	75,000
Valerie Schwartz	-	500	-	-	500
Total net assets with temporary donor restrictions	<u>\$ 10,512,357</u>	<u>\$ 2,006,654</u>	<u>\$ (3,306,670)</u>	<u>\$ 519,663</u>	<u>\$ 9,732,004</u>
Total net assets with donor restrictions	<u>\$ 64,004,678</u>	<u>\$ 2,006,654</u>	<u>\$ (3,306,670)</u>	<u>\$ 532,032</u>	<u>\$ 63,236,964</u>